ID   T449
AC   CVCL_M807
SY   93449; LPS449
DR   Cosmic; 2307716
DR   TOKU-E; 4077
DR   Wikidata; Q54971558
RX   PubMed=17354236;
RX   PubMed=22911243;
RX   PubMed=24726063;
DI   NCIt; C6505; Atypical lipomatous tumor/well differentiated liposarcoma
DI   ORDO; Orphanet_99971; Well-differentiated liposarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_M808 ! T778
SX   Female
AG   68Y
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 21-03-23; Version: 10
//
RX   PubMed=17354236; DOI=10.1002/ijc.22643;
RA   Muller C.R., Paulsen E.B., Noordhuis P., Pedeutour F., Saeter G.,
RA   Myklebost O.;
RT   "Potential for treatment of liposarcomas with the MDM2 antagonist
RT   Nutlin-3A.";
RL   Int. J. Cancer 121:199-205(2007).
//
RX   PubMed=22911243; DOI=10.1155/2012/148614;
RA   Stratford E.W., Castro R., Daffinrud J., Skarn M., Lauvrak S.,
RA   Munthe E., Myklebost O.;
RT   "Characterization of liposarcoma cell lines for preclinical and
RT   biological studies.";
RL   Sarcoma 2012:148614.1-148614.9(2012).
//
RX   PubMed=24726063; DOI=10.1186/1756-9966-33-33;
RA   Koelsche C., Renner M., Hartmann W., Brandt R., Lehner B.,
RA   Waldburger N., Alldinger I., Schmitt T., Egerer G., Penzel R.,
RA   Wardelmann E., Schirmacher P., von Deimling A., Mechtersheimer G.;
RT   "TERT promoter hotspot mutations are recurrent in myxoid liposarcomas
RT   but rare in other soft tissue sarcoma entities.";
RL   J. Exp. Clin. Cancer Res. 33:33.1-33.8(2014).
//